
To investigate the long term effect of hormone replacement therapy on cardiovascular outcomes in recently zzso zzso 

Open label, zzso controlled zzso 

Denmark, zzso 

zzso healthy women aged zzso who were recently zzso or had zzso symptoms in combination with recorded zzso serum zzso stimulating hormone zzso 502 women were randomly allocated to receive hormone replacement therapy and 504 to receive no treatment zzso Women who had undergone zzso were included if they were aged zzso and had recorded values for zzso serum zzso stimulating zzso 

In the treatment group, women with an intact zzso were treated with zzso zzso and zzso zzso and women who had undergone zzso received 2 zzso zzso a zzso zzso was stopped after about 11 years zzso to adverse reports from other trials, but participants were followed for death, cardiovascular disease, and cancer for up to 16 zzso zzso analyses were carried out on women who took more than zzso of the prescribed treatment for five zzso 

The primary zzso was a composite of death, admission to hospital for heart failure, and zzso zzso 

At inclusion the women on average were aged 50 and had been zzso for seven zzso After 10 years of intervention, 16 women in the treatment group experienced the primary composite zzso compared with 33 in the control group zzso ratio zzso zzso confidence zzso zzso to zzso zzso and 15 died compared with 26 zzso zzso to zzso zzso The reduction in cardiovascular events was not associated with an increase in any cancer zzso in treated group v 39 in control group, zzso zzso to zzso zzso or in breast cancer (10 in treated group v 17 in control group, zzso zzso to zzso zzso The hazard ratio for deep vein zzso (2 in treated group v 1 in control zzso was zzso zzso to zzso and for stroke (11 in treated group v 14 in control zzso was zzso zzso to zzso After 16 years the reduction in the primary composite outcome was still present and not associated with an increase in any zzso 

After 10 years of zzso treatment, women receiving hormone replacement therapy early after menopause had a significantly reduced risk of zzso heart failure, or zzso zzso without any apparent increase in risk of cancer, zzso zzso or zzso 

zzso zzso 

